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Boca Raton Regional Hospital
• Not-for-profit 400 bed advanced academic tertiary medical center





– Emergency Medicine 
– Neurosciences
• Predominantly elderly patient population
• Highest ranked hospital in Palm Beach County 
– Listed by U.S. News & World Report 2019-2020
• Lynn Cancer Institute is one of the largest cancer programs in the state of Florida and 
accredited by the American College of Surgeons
Presentation Objective 
Assess the risk of acute kidney injury in 
patients receiving vancomycin plus 
piperacillin-tazobactam compared to 
vancomycin plus cefepime
Background
• Vancomycin is a commonly used antibiotic to cover 
methicillin-resistant Staphylococcus aureus (MRSA)
• It is often used in combination with broad spectrum 
antibiotics such as piperacillin-tazobactam or cefepime 
for empiric therapy in commonly encountered hospital 
infections
Background
• The mechanism by which vancomycin causes renal injury 
is not well understood. Accumulation of vancomycin in the 
proximal renal tubule may lead to acute tubular necrosis 
and glomerular destruction.1
• Semisynthetic penicillins, such as piperacillin, exhibit high 
concentrations throughout the nephron and mechanism 
of nephrotoxicity is likely acute interstitial nephritis.1




Hammond D. A. et al. Clin 
Infect Dis. 2017;64(5):666-
674
The primary outcome was 
incidence of AKI
Concomitant vancomycin and piperacillin-
tazobactam was associated with increased 
risk of AKI (OR 3.12; 95% CI, 2.04-4.78; P 
<0.001)
Luther M. K. et al. Crit 
Care Med 2018; 46:12-20
The primary outcome was AKI, as 
defined by the individual study 
(AKIN, RIFLE, KDIGO)
• Vancomycin plus piperacillin-
tazobactam vs vancomycin 
monotherapy (OR, 3.40; 95% CI, 2.57–
4.50) 
• Vancomycin plus cefepime or 
carbapenem vs vancomycin plus 
piperacillin-tazobactam (OR, 2.68; 95% 
CI, 1.83–3.91) 
KDIGO – AKI Definition
Stage Serum creatinine Urine output
1 1.5 – 1.9 times baseline OR≥ 0.3 mg/dL increase
< 0.5 mL/kg/hour for 6 – 12 
hours
2 2 – 2.9 times baseline < 0.5 mL/kg/hour for ≥ 12 hours
3
3 times baseline OR 
Increase in serum creatinine to ≥ 4 mg/dL 
OR
Initiation of renal replacement therapy OR, 
In patients < 18 years, decrease in eGFR 
to < 35 mL/min/1.73 m2
< 0.3 mL/kg/hour for ≥ 24 
hours OR
Anuria for ≥ 12 hours
Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012; 120:179–184.
Purpose
Compare the incidence of acute kidney injury in 
patients receiving vancomycin plus piperacillin-
tazobactam compared to vancomycin plus 
cefepime in our institution 
Methods
Retrospective, single center, observational study 
Conducted between January 1st, 2019 and December 
31st, 2019
Patients were identified by a computer-generated 
report through Discern Analytics Reporting Portal 
Program
Statistical Analysis
N-1 Chi-squared test was used for 
evaluation of nominal data
Comparison between continuous data 
was performed using Student’s t test
Inclusion and Exclusion Criteria
Inclusion
• Patients ≥ 18 years of age
• Patients on vancomycin plus piperacillin-tazobactam or vancomycin plus 
cefepime for more than 48 hours
Exclusion
• Patients already experiencing an AKI
• Patients with stage 4 CKD
• Patients on renal replacement therapy
• Patients with allergies to any of the study medications
Study Outcomes
Primary Endpoint
• The incidence of acute 




to vancomycin plus 
cefepime
Secondary Endpoints 
• Length of hospital stay
• Increase in creatinine 
to 2 times baseline






147 met inclusion 
criteria
72 patients in 
vancomycin plus 
cefepime









Male sex 39 (52%) 38 (53%) 0.93
Age (years) 67.3 ± 19.59 71.03 ± 15.17 0.19
Baseline SCr (mg/dL) 0.91 ± 0.3 0.9 ± 0.9 0.92
ICU 12 (16%) 10 (14% ) 0.72
Duration of antibiotic 
therapy (days) 5.6 ± 2.5 5.3 ± 2.6 0.45
Comorbidities
CDK 6 (8%) 5 (7%) 0.81
Diabetes 15 (20%) 13 (18%) 0.76
COPD 10 (13%) 6 (8%) 0.33
CHF 6 (8%) 2 (3%) 0.16
Malignancy 17 (23%) 25 (35%) 0.11
ABBREVATIONS: CKD, chronic kidney disease; COPD, chronic obstructive 
pulmonary disease; CHF, chronic heart failure; vanc, vancomycin; pip-tazo, 
piperacillin-tazobactam; cef, cefepime 




Bacteremia 4 (5%) 2 (3%) 0.44
Cellulitis 13 (17%) 14 (19%) 0.74
Other* 9 (12%) 14 (19%) 0.22
Osteomyelitis 2 (3%) 4 (6%) 0.38
Pneumonia** 36 (48%) 21 (29%) 0.02
Sepsis-empiric 10 (13%) 15 (21%) 0.23
SSTI 1 (1%) 3 (4%) 0.29
ABBREVATIONS: SSTI, skin and soft tissue infection; vanc, vancomycin; 
pip-tazo, piperacillin-tazobactam; cef, cefepime  
*Meningitis, neutropenic fever, UTI, joint infection, other





ACEi/ARB 13 (17%) 10 (13%) 0.57
Acyclovir 1 (1%) 1 (1%) 1.00
Loop diuretics 21 (28%) 13 (18%) 0.15
NSAIDs 3 (4%) 5 (7%) 0.43
Vasopressors 4 (5%) 4 (6%) 1.00
Radiocontrast media 3 (4%) 0 (0%) 0.09
ABBREVATIONS:  vanc, vancomycin; pip-tazo, piperacillin-tazobactam; cef, 
cefepime; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II 






























Length of hospital stay (days) 14.28 ± 17.9 11.76 ± 9.2 0.28
SCr ≥ 2 times baseline 6 (8%) 0 (0%) 0.02
Nephrologist consult 2/22 (9%) 0/11 (0%) 0.54
ABBREVATIONS:  vanc, vancomycin; pip-tazo, piperacillin-tazobactam; cef, cefepime
Conclusion
• This study showed that concomitant use of vancomycin 
plus piperacillin-tazobactam puts patients at an increased 
risk for AKI
• The severity of AKI was worse in the vancomycin plus 
piperacillin-tazobactam group compared to vancomycin 
plus cefepime group
• Clinicians should be aware of this potential risk and be 






The use of vancomycin plus piperacillin-tazobactam is 
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